Michael Sefton to receive Lifetime Achievement Award from the Tissue Engineering & Regenerative Medicine International Society

University of Toronto biomedical engineering University Professor Michael Sefton (IBBME, ChemE) has been named this year’s recipient of the Lifetime Achievement Award from the Tissue Engineering & Regenerative Medicine International Society (TERMIS). The award, issued by the organization’s Americas chapter, recognizes his immense contributions to the fields of tissue engineering and regenerative medicine.

Sefton joins an elite list of renowned recipients, including MIT professor of chemical engineering Robert Langer and founding director of the University of Pittsburgh’s McGowan Institute for Regenerative Medicine, Alan Russell.

Sefton has made significant contributions to research advances in biomaterials, biomedical engineering and regenerative medicine. He was one of the first to combine living cells with polymers, effectively launching the field now now called tissue engineering. Recently, his lab has created biomaterials that actively promote the growth of blood vessels — such materials accelerate wound healing and support the development of lab-grown tissues.

Among his numerous awards and accolades, Sefton received the European Society for Biomaterials International Award in April, the Terumo Global Science Prize in January and was named last year to the U.S. National Institute of Medicine. He holds the title of University Professor, the highest academic rank at the University of Toronto, reserved for less than two per cent of tenured faculty.

A leader in his professional community, he served as president of the U.S. Society for Biomaterials in 2005 and has spearheaded several programs to advance the field. From 1999 to 2005, Sefton was director of the Institute of Biomaterials & Biomedical Engineering (IBBME) leading its development into one of the top institutes of its kind in North America.

“This is a terrific recognition of Michael’s outstanding efforts throughout his career in advancing the field of tissue engineering,” said IBBME director Professor Christopher Yip.

Sefton will be presented with the award at the 2016 TERMIS-AM conference to take place from December 11 to 14 in San Diego, California.

Source: http://goo.gl/UtBV0Y

Comments

The Dawn Of A New Era Of Regenerative Medicine: Tissue Engineering Comes Of Age

The Dawn Of A New Era Of Regenerative Medicine: Tissue Engineering Comes Of Age The field of regenerative medicine reached a remarkable milestone recently when four women regained full sexual function after the successful implantation of lab-grown vaginas created from their own cells. The women, aged thirteen to eighteen, were born with a rare medical condition called Mayer-Rokitansky-Küster-Hauser syndrome (MRKHS) which left them with an abnormal or missing vagina. Each woman underwent a newly engineered procedure that involved taking samples of the patient's own cells and growing them into tissue. This tissue was then placed on a scaffold that was hand-sewn with collagen-like fibers and uniquely shaped to fit each woman’s vaginal cavity. Once the organ fully matured, it was implanted into a canal in each woman’s pelvis, along with the hand-sewn scaffolding. Within six months, the biodegradable scaffolding dissolved and, in each of the four women, the lab-grown vaginas began fun...

Gene Therapy for Cancer: A Promising Hope on the Horizon

Gene therapy, a revolutionary approach in modern medicine, holds immense potential for treating cancer by directly altering a patient's genetic makeup to fight the disease. While still in its early stages, it has shown remarkable promise in clinical trials, offering hope for patients with previously untreatable forms of cancer. How does Gene Therapy work for Cancer? Cancer arises from genetic mutations that cause cells to grow and divide uncontrollably. Gene therapy aims to correct these mutations or introduce new genes that can suppress cancer growth. This can be achieved through various methods, including: Replacing faulty genes: Viral vectors are used to deliver healthy copies of genes to cancer cells, replacing the non-functional ones. Silencing cancer-causing genes: Gene therapy can be used to switch off genes that promote cancer cell growth. Introducing genes for immune system activation: Certain genes can be introduced to boost the immune system's ability to recognize a...

Black fungus detected in Covid-19 survivors, 8 lose eyesight in Surat | MUCORMYCOSIS

Black fungus detected in Covid-19 survivors, 8 lose eyesight in Surat | MUCORMYCOSIS At least 40 cases of mucormycosis, also known as black fungus, have been reported from Surat in Gujarat among those who have recovered from Covid-19. Of the 40, eight have lost their eyesight. What is this infection and who is more vulnerable? Cases of mucormycosis, commonly known as black fungus, have been reported from Gujarat among those who have recovered from Covid-19. The number of such cases has increased as Gujarat sees an exponential rise in coronavirus infections. At least eight persons were reported to have lost their eyesight in Surat due to mucormycosis (MM) after recovering from Covid-19. They had to be admitted to hospitals for the sudden loss of vision. In the past 15 days, Surat has reported at least 40 cases of mucormycosis or black fungus including eight who have lost their eyesight. The infection, triggered by Covid-19, is treatable but if left untreated or if the treatment is ...

Stem Cells Therapy in India

Search This Blog